0QNO Stock Overview
Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Lonza Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 514.20 |
| 52 Week High | CHF 589.00 |
| 52 Week Low | CHF 315.80 |
| Beta | 0.64 |
| 11 Month Change | -5.18% |
| 3 Month Change | -8.44% |
| 1 Year Change | 46.90% |
| 33 Year Change | -28.20% |
| 5 Year Change | 51.55% |
| Change since IPO | 505.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QNO | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | -7.7% | -10.6% | 0.8% |
| 1Y | 46.9% | -30.2% | 6.6% |
Return vs Industry: 0QNO exceeded the UK Life Sciences industry which returned -31.5% over the past year.
Return vs Market: 0QNO exceeded the UK Market which returned 6.1% over the past year.
Price Volatility
| 0QNO volatility | |
|---|---|
| 0QNO Average Weekly Movement | 3.0% |
| Life Sciences Industry Average Movement | 6.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0QNO has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0QNO's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1897 | 17,834 | Wolfgang Wienand | www.lonza.com |
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing.
Lonza Group AG Fundamentals Summary
| 0QNO fundamental statistics | |
|---|---|
| Market cap | CHF 37.67b |
| Earnings (TTM) | CHF 573.00m |
| Revenue (TTM) | CHF 6.70b |
65.7x
P/E Ratio5.6x
P/S RatioIs 0QNO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QNO income statement (TTM) | |
|---|---|
| Revenue | CHF 6.70b |
| Cost of Revenue | CHF 4.29b |
| Gross Profit | CHF 2.41b |
| Other Expenses | CHF 1.84b |
| Earnings | CHF 573.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Jan 29, 2025
| Earnings per share (EPS) | 7.93 |
| Gross Margin | 36.01% |
| Net Profit Margin | 8.56% |
| Debt/Equity Ratio | 40.3% |
How did 0QNO perform over the long term?
See historical performance and comparison